Mizuho Raises Solventum Target to $100 After Optimistic Dental Survey, Acera Deal
Mizuho upgraded Solventum’s rating to Outperform, raising its price target to $100 from $85 after an annual dental industry survey showed improved consumables and patient volume expectations. Solventum completed its $725 million acquisition of Acera Surgical with potential $125 million in milestone payments, expecting accretion in 2027.
1. Mizuho Upgrade Details
Mizuho raised Solventum’s rating from Neutral to Outperform and increased its price target to $100 from $85, driven by an annual dental industry survey indicating stronger expectations for consumables and patient volumes.
2. Stifel Rating Increase
Stifel maintained its Buy rating on Solventum and lifted its price target to $105 from $88, highlighting a favorable outlook for large-cap MedTech following 2025 pressures.
3. Acera Acquisition Impact
Solventum finalized its acquisition of Acera Surgical for $725 million upfront, plus up to $125 million in milestone-based payments, enhancing its MedSurg portfolio and projected to be accretive to adjusted EPS from 2027.